Subscribe
  • Home
  • Issues
    • Latest Issue
    • Issue Archive
    • Special Issues
      • 2022 Midyear Review: Non–Small-Cell Lung Cancer
      • 2022 Oncology Biosimilar Guide to Patient Support Services
      • 2022 Breast Cancer Guide to Patient Support Services
  • Browse By Topic
    • Practice Management
    • Financial Management
    • Reimbursement
    • Health Policy
    • Quality Care
    • ICD Codes
    • Survivorship
    • FDA Approvals, News & Updates
    • In the News
  • Guide to Patient Support Services
    • Index
    • Introduction
    • 2023 Spotlight
  • Conference Correspondent
    • ASCO 2022 - Wrap Up
    • NSCLC IO 2022 - Midyear Review
    • SABCS 2021 Wrap-Up
    • Dual IO 2021 Year in Review
  • Web Exclusives
    • Web Exclusive Articles
    • Videos
    • Interview with the Innovators
    • Webinars
    • Rapid Reactions
    • In the News
    • Quick Quiz
    • Multiple Myeloma Monthly Minutes
    • Melanoma Monthly Minutes
    • Press Releases
    • Women's Health Monthly Minutes
    • Lung Cancer Monthly Minutes
    • Gastrointestinal Cancer Monthly Minutes

ASH 2016 Highlights

CAR T-Cell Therapy Succeeds in Aggressive Lymphoma
By Phoebe Starr
ASH 2016 Highlights
February 2017, Vol 7, No 2
Read More ›

Obinutuzumab Prolongs Survival in Follicular Lymphoma
By Phoebe Starr
ASH 2016 Highlights
February 2017, Vol 7, No 2
Read More ›

Glasdegib, a Hedgehog Inhibitor, Nearly Doubles Survival in Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
By Wayne Kuznar
ASH 2016 Highlights
February 2017, Vol 7, No 2
Read More ›

Triplet Therapy That Includes Elotuzumab Stops Progression of High-Risk Smoldering Multiple Myeloma
By Wayne Kuznar
ASH 2016 Highlights, Multiple Myeloma, Hematologic Malignancies
February 2017, Vol 7, No 2
Read More ›

Strategies to Reduce the Use of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia
By Phoebe Starr
ASH 2016 Highlights
February 2017, Vol 7, No 2
Read More ›

R-CHOP Prevails Over Dose-Adjusted EPOCH-R as Standard of Care for Diffuse Large B-Cell Lymphoma
By Phoebe Starr
ASH 2016 Highlights
February 2017, Vol 7, No 2
Read More ›

New Value Model Incorporates Long-Term Adverse Effects of Cancer Drugs
By Chase Doyle
ASH 2016 Highlights
February 2017, Vol 7, No 2
Read More ›

View the Latest Issue of OPM
View the Latest Issue
Read Issue

Top Trending Articles

1.
Specialty Carve-Outs: What Are the Implications for Patients and Practices?
By Dawn Holcombe, MBA, FACMPE, ACHE
2.
New Policies Regarding Intravenous Iron Replacement Are Creating Conundrum for Providers and Payers
By Dawn Holcombe, MBA, FACMPE, ACHE
3.
2023 Spotlight: Amgen
  • Home
  • Issues
    • Latest Issue
    • Issue Archive
    • Special Issues
      • 2022 Midyear Review: Non–Small-Cell Lung Cancer
      • 2022 Oncology Biosimilar Guide to Patient Support Services
      • 2022 Breast Cancer Guide to Patient Support Services
  • Browse By Topic
    • Practice Management
    • Financial Management
    • Reimbursement
    • Health Policy
    • Quality Care
    • ICD Codes
    • Survivorship
    • FDA Approvals, News & Updates
    • In the News
  • Guide to Patient Support Services
    • Index
    • Introduction
    • 2023 Spotlight
  • Conference Correspondent
    • ASCO 2022 - Wrap Up
    • NSCLC IO 2022 - Midyear Review
    • SABCS 2021 Wrap-Up
    • Dual IO 2021 Year in Review
  • Web Exclusives
    • Web Exclusive Articles
    • Videos
    • Interview with the Innovators
    • Webinars
    • Rapid Reactions
    • In the News
    • Quick Quiz
    • Multiple Myeloma Monthly Minutes
    • Melanoma Monthly Minutes
    • Press Releases
    • Women's Health Monthly Minutes
    • Lung Cancer Monthly Minutes
    • Gastrointestinal Cancer Monthly Minutes
CONNECT
Subscribe
  • About
    • About OPM
    • Mission Statement
    • Editorial Board
    • AOPM
    • Contact
  • Contribute
    • Submit a Manuscript
    • Author Guidelines
  • Connect
    • Join Us on LinkedIn
Sign Up for Oncology News

Subscribe to recieve the free, monthly OPM print publication and OPM weekly e‑newsletter.

Subscribe
© The Lynx Group, LLC. All Rights Reserved. Privacy Policy.